Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study

Authors

K. Murayama (ORCID: https://orcid.org/0000-0003-3301-9966)
Jun Sato
Nobuaki Matsubara (ORCID: https://orcid.org/0000-0002-9203-4245)
Toshio Kawata
Kunihiro Iwata (ORCID: https://orcid.org/0000-0002-4873-8982)
Noboru Yamamoto (ORCID: https://orcid.org/0000-0002-0787-2851)
Hisashi Kawasumi (ORCID: https://orcid.org/0000-0002-5981-2383)
Aleksandra E. Kmieciak
Takao Fujisawa (ORCID: https://orcid.org/0009-0002-3438-5757)
Yusuke Takahashi
Yasutoshi Kuboki (ORCID: https://orcid.org/0000-0003-3675-953X)
Yuki Katsuya (ORCID: https://orcid.org/0000-0002-2127-3601)
Daniel Slade (ORCID: https://orcid.org/0000-0001-6063-1283)
Hiromichi Nakajima (ORCID: https://orcid.org/0000-0001-6401-4258)
Takafumi Koyama (ORCID: https://orcid.org/0000-0002-2791-5572)
Masahiro Nii

Institutions

AstraZeneca (United Kingdom) (GB)
AstraZeneca (Japan) (JP)
National Cancer Center Hospital East (JP)
Tokyo National Hospital (JP)

Publication Details

Journal: Investigational New Drugs
Published: 2025-12-01
DOI: https://doi.org/10.1007/s10637-025-01592-x
Primary Topic: Melanoma and MAPK Pathways
Type: article
Field-Weighted Citation Impact: 0.00

Funders

AstraZeneca

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study

K. Murayama, Jun Sato, Nobuaki Matsubara, Toshio Kawata et al.

Dec 1, 2025

Investigational New Drugs

Melanoma and MAPK Pathways

article

Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study

K. Murayama, Jun Sato, Nobuaki Matsubara, Toshio Kawata, Kunihiro Iwata, Noboru Yamamoto, Hisashi Kawasumi, Aleksandra E. Kmieciak, Takao Fujisawa, Yusuke Takahashi, Yasutoshi Kuboki, Yuki Katsuya, Daniel Slade, Hiromichi Nakajima, Takafumi Koyama, Masahiro Nii

December 1, 2025article en

Abstract

No abstract available for this paper.

Investigational New DrugsVol. 43(6)

AstraZeneca (United Kingdom) (GB), AstraZeneca (Japan) (JP), National Cancer Center Hospital East (JP), Tokyo National Hospital (JP)

AstraZeneca

Openalex Percentile: Top 65%

Melanoma and MAPK Pathways

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study — K. Murayama, Jun Sato, et al. · Investigational New Drugs (2025) | TGRS Research Map | TGRS